Timber Pharmaceuticals — Corporate Update (December 2020)
13 slides from Timber Pharmaceuticals's corporate update, Dec 17, 2020
Slide 1: Business Update Conference Call
Business Update Conference Call NYSE American: TMBR December 17, 2020
Slide 2: Safe Harbor Statement
Safe Harbor Statement Certain statements contained in this PowerPoint presentation describing Timber’s technology and development program, including, without limitation, statements containing the words “expects,” “anticipates,” “believes,” and words of similar import, constitute “forward - looking s
Slide 3: Rare Dermatologic Diseases
3 • Rare dermatological diseases are underrepresented in drug development and pharmaceutical company sponsored trials • Many orphan and rare dermatology disorders are associated with significant quality of life impairments, particularly if the disease is insufficiently controlled • Disease visibilit
Slide 4: Timber Business Model
4 Timber Business Model • Focused on Orphan Drug Indications and Leveraging the 505(b)(2) pathway • Why Orphan Drugs? • Timber will be first to market by pursuing conditions for which there are no current FDA approved treatments • Requires smaller and less costly drug trials with greater flexibility
Slide 5: TMB for Congenital Ichthyosis
5 TMB - 001 for Congenital Ichthyosis A rare disorder of keratinization affecting ~ 80,000 people in the U.S. (>1.5 million globally) Prevalence • X - Linked Ichthyosis has a prevalence of 1:2,000 - 1:6,000 males • Lamellar Ichthyosis has a prevalence of 1:100,000 - 200,000 Quality of life is signif
Slide 6: TMB-001 Topical Isotretinoin in CI
6 Isotretinoin is widely viewed as the most effective therapy for several skin conditions, including ichthyosis, but it is only available orally, where high dose, chronic oral therapy cannot be tolerated due to systemic toxicity TMB - 001 utilizes proprietary IPEG™ delivery system to target isotreti
Slide 7: TMB for Facial Angiofibromas in Tuberous Sclerosis Complex
7 TMB - 002 for Facial Angiofibromas in Tuberous Sclerosis Complex TSC is a multisystem genetic disorder affecting approximately 50,000 people in the US TSC is caused by the unregulated activation of the mammalian target of rapamycin (mTOR) pathway, resulting in the growth of hamartomas in multiple
Slide 8: TMB Topical Rapamycin (Pascomer)
8 TMB - 002 Topical Rapamycin (Pascomer®) Potentially the First Commercially Available, High - Quality Topical Formulation of Rapamycin with Broad Access Proprietary topical formulation of rapamycin (1.0%, 0.5%, and 0.1%) • Additional 5% strength assessed in preclinical toxicity studies Utilizes tra
Slide 9: Strategic Pipeline in Rare Dermatologic Disease
9 Strategic Pipeline in Rare Dermatologic Disease NYSE American: TMBR
Slide 10: Significant Clinical Milestones on a Quarterly Basis over next 12 months
10 Significant Clinical Milestones on a Quarterly Basis over next 12 months TMB - 001 TMB - 002 Q3 2020 Phase 2B – Opening of all sites Phase 2B – Opening of all sites Q4 2020 Reach 50% enrollment of the Phase 2B trial Reach 50% enrollment of the Phase 2B trial Q1 2021 Complete enrollment Complete e
Slide 11: Financial and Capitalization Highlights
11 Financial and Capitalization Highlights On May 18, 2020, upon closing of its merger with a NYSE - listed company, Timber also completed a financing with gross proceeds of $25 million, which included the conversion of a $5 million bridge note previously issued by Timber and the issuance of Series
Slide 12: Key Takeaways
12 Key Takeaways • Positioned to become a leading Dermatology company with a focus on orphan diseases, led by a management team with a proven track record in development and commercialization • High potential, late stage, lower risk multi - product candidate pipeline • Proven clinical Proof of Conce
Slide 13: Building Bridges in Medical Dermatology
Building Bridges in Medical Dermatology For additional Investor Information please contact: John Koconis Stephanie Prince CEO PCG Advisory [email protected] [email protected] (646) 863 - 6341 Thank You www.timberpharma.com
Timber Pharmaceuticals — Corporate Update (December 2020) on 6ix